Opioid Labeling: Congress Wants Box Warning On Immediate-Release Products
This article was originally published in The Pink Sheet Daily
Executive Summary
House Energy & Commerce Committee asks FDA to explain discrepancy in labeling between immediate release and extended release/long-acting formulations, questions effectiveness of opioid REMS.